Combination of novel systemic agents and radiotherapy for solid tumors - Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicity

被引：9

作者：

Arcangeli, Stefano ^{[1
,2
]}

Jereczek-Fossa, Barbara Alicia ^{[3
]}

Alongi, Filippo ^{[4
]}

Aristei, Cynthia ^{[5
]}

Becherini, Carlotta ^{[6
]}

Belgioia, Liliana ^{[7
,8
]}

Buglione, Michela ^{[9
,10
]}

Caravatta, Luciana ^{[11
]}

D'Angelillo, Rolando Maria ^{[12
]}

Filippi, Andrea Riccardo ^{[13
]}

Fiore, Michele ^{[12
]}

Genovesi, Domenico ^{[11
]}

Greco, Carlo ^{[12
]}

Livi, Lorenzo ^{[6
]}

Magrini, Stefano Maria ^{[9
,10
]}

Marvaso, Giulia ^{[3
]}

Mazzola, Rosario ^{[4
]}

Meattini, Icro ^{[6
]}

Merlotti, Anna ^{[14
]}

Palumbo, Isabella ^{[5
]}

Pergolizzi, Stefano ^{[15
]}

Ramella, Sara ^{[12
]}

Ricardi, Umberto ^{[16
]}

Russi, Elvio ^{[14
]}

Trovo, Marco ^{[17
]}

Sindoni, Alessandro ^{[19
]}

Valentini, Vincenzo ^{[18
]}

Corvo, Renzo ^{[8
]}

机构：

[1] Policlin S Gerardo, Dept Radiat Oncol, Milan, Italy

[2] Univ Milano Bicocca, Milan, Italy

[3] IEO European Inst Oncol IRCCS, Dept Radiat Oncol, Milan, Italy

[4] Univ Brescia, Dept Radiat Oncol, Sacro Cuore Don Calabria Canc Care Ctr, Brescia, Italy

[5] Univ Perugia, Perugia Gen Hosp, Radiat Oncol Sect, Dept Surg & Biomed Sci, Perugia, Italy

[6] Univ Florence, Dept Expt & Clin Biomed Sci, Radiotherapy Unit, Florence, Italy

[7] Osped Policlin San Martino, Dept Radiat Oncol, Genoa, Italy

[8] Univ Genoa, Genoa, Italy

[9] Univ Brescia, Dept Radiat Oncol, Brescia, Italy

[10] Spedali Civili Hosp, Brescia, Italy

[11] Univ G dAnnunzio, SS Annunziata Hosp, Dept Radiat Oncol, Chieti, Italy

[12] Campus BioMed Univ, Radiotherapy Unit, Rome, Italy

[13] Fdn IRCCS Policlin San Matteo, Dept Radiat Oncol, Pavia, Italy

[14] S Croce & Carle Teaching Hosp, Dept Radiat Oncol, Cuneo, Italy

[15] Univ Messina, Dept Biomed Sci & Morphol & Funct Images, Messina, Italy

[16] Univ Turin, Dept Oncol, Turin, Italy

[17] Azienda Sanitaria Univ Integrata Udine, Dept Radiat Oncol, Udine, Italy

[18] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli, Gemelli Adv Radiat Therapy Ctr, Rome, Italy

[19] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Rome, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2019年 / 134卷

关键词：

Radiotherapy; Systemic compounds; Toxicity; ADVANCED RECTAL-CANCER; RANDOMIZED PHASE-II; SQUAMOUS-CELL CARCINOMA; RADIATION-RECALL DERMATITIS; LOCALLY ADVANCED HEAD; HEDGEHOG PATHWAY INHIBITOR; MELANOMA BRAIN METASTASES; RESISTANT PROSTATE-CANCER; STEREOTACTIC RADIOSURGERY; ESOPHAGEAL CANCER;

D O I：

10.1016/j.critrevonc.2018.11.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Clinical development and use of novel systemic agents in combination with radiotherapy (RT) is at nowadays most advanced in the field of treatment of solid tumors. Although for many of these substances preclinical studies provide sufficient evidences on their principal capability to enhance radiation effects, the majority of them have not been investigated in even phase I clinical trials for safety in the context of RT. In clinical practice, unexpected acute and late side effects may emerge especially in combination with RT. As a matter of fact, despite combined modality treatment holds potential for enhancing the therapeutic ratio, some concerns are raised from the lack of high-quality clinical data to guide the care of patients who are treated with novel compounds in conjunction with RT. The aim of this review is to provide, from a radio-oncological point of view, an overview of the most advanced combined treatment concepts for solid tumors focusing on treatment toxicity.

引用

页码：104 / 119

页数：16

共 157 条

[1] Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1-3 newly diagnosed brain metastases [J].

Ahluwalia, Manmeet S. ;

Chao, Samuel T. ;

Parsons, Michael W. ;

Suh, John H. ;

Wang, Ding ;

Mikkelsen, Tom ;

Brewer, Cathy J. ;

Smolenski, Kathy N. ;

Schilero, Cathy ;

Rump, Matthew ;

Elson, Paul ;

Angelov, Lilyana ;

Barnett, Gene H. ;

Vogelbaum, Michael A. ;

Weil, Robert J. ;

Peereboom, David M. .

JOURNAL OF NEURO-ONCOLOGY, 2015, 124 (03) :485-491

[2] Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy [J].

Ahmed, K. A. ;

Stallworth, D. G. ;

Kim, Y. ;

Johnstone, P. A. S. ;

Harrison, L. B. ;

Caudell, J. J. ;

Yu, H. H. M. ;

Etame, A. B. ;

Weber, J. S. ;

Gibney, G. T. .

ANNALS OF ONCOLOGY, 2016, 27 (03) :434-441

[3]

Ahn PH, 2016, AM J CLIN ONCOL

[4] Locally advanced basal-cell carcinoma: Combined alternative treatments beyond surgery [J].

Amici, J. -M. ;

Beylot-Barry, M. .

ANNALES DE CHIRURGIE PLASTIQUE ESTHETIQUE, 2015, 60 (04) :321-325

[5] Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522 [J].

Ang, K. Kian ;

Zhang, Qiang ;

Rosenthal, David I. ;

Nguyen-Tan, Phuc Felix ;

Sherman, Eric J. ;

Weber, Randal S. ;

Galvin, James M. ;

Bonner, James A. ;

Harris, Jonathan ;

El-Naggar, Adel K. ;

Gillison, Maura L. ;

Jordan, Richard C. ;

Konski, Andre A. ;

Thorstad, Wade L. ;

Trotti, Andy ;

Beitler, Jonathan J. ;

Garden, Adam S. ;

Spanos, William J. ;

Yom, Sue S. ;

Axelrod, Rita S. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2940-+

[6] Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG) [J].

Anker, Christopher J. ;

Grossmann, Kenneth F. ;

Atkins, Michael B. ;

Suneja, Gita ;

Tarhini, Ahmad A. ;

Kirkwood, John M. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 95 (02) :632-646

[7] Severe Liver and Skin Toxicity After Radiation and Vemurafenib in Metastatic Melanoma [J].

Anker, Christopher J. ;

Ribas, Antoni ;

Grossmann, Allie H. ;

Chen, Xinjian ;

Narra, Krishna K. ;

Akerley, Wallace ;

Andtbacka, Robert H. I. ;

Noyes, Robert Dirk ;

Shrieve, Dennis C. ;

Grossmann, Kenneth F. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) :E283-E287

[8]

[Anonymous], 2013, J CLIN ONCOL

[9] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[10] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].